CN114901812A - 使用环状dna将抗原特异性受体基因导入至t细胞基因组的方法 - Google Patents
使用环状dna将抗原特异性受体基因导入至t细胞基因组的方法 Download PDFInfo
- Publication number
- CN114901812A CN114901812A CN202080090344.XA CN202080090344A CN114901812A CN 114901812 A CN114901812 A CN 114901812A CN 202080090344 A CN202080090344 A CN 202080090344A CN 114901812 A CN114901812 A CN 114901812A
- Authority
- CN
- China
- Prior art keywords
- vector
- nucleic acid
- sequence
- antigen receptor
- nuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019206448 | 2019-11-14 | ||
| JP2019-206448 | 2019-11-14 | ||
| PCT/JP2020/042429 WO2021095847A1 (ja) | 2019-11-14 | 2020-11-13 | 抗原特異的受容体遺伝子を環状dnaを用いてt細胞ゲノムに導入する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114901812A true CN114901812A (zh) | 2022-08-12 |
Family
ID=75912989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080090344.XA Pending CN114901812A (zh) | 2019-11-14 | 2020-11-13 | 使用环状dna将抗原特异性受体基因导入至t细胞基因组的方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230250415A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4060038A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2021095847A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114901812A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202124718A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021095847A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI921044B (zh) * | 2025-02-12 | 2026-04-01 | 宏碁股份有限公司 | 以胺基酸與來源蛋白關係產生負樣本的方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105683375A (zh) * | 2013-11-06 | 2016-06-15 | 国立大学法人广岛大学 | 用于插入核酸的载体 |
| WO2018025206A1 (en) * | 2016-08-02 | 2018-02-08 | Kyoto University | Method for genome editing |
| WO2019073965A1 (ja) * | 2017-10-10 | 2019-04-18 | 国立大学法人広島大学 | エフェクターT細胞(Teff)抗原受容体を用いた抗原特異的制御性T細胞(Treg)の作出技術 |
| WO2019073964A1 (ja) * | 2017-10-10 | 2019-04-18 | 国立大学法人広島大学 | Platinum TALENを用いたT細胞受容体の完全置換技術 |
| WO2019084552A1 (en) * | 2017-10-27 | 2019-05-02 | The Regents Of The University Of California | TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59942B2 (ja) | 1974-01-11 | 1984-01-09 | 株式会社日立製作所 | ホウデンガタイオンゲンヨウデンゲン |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| GB201407852D0 (en) * | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| JP6246258B2 (ja) | 2016-04-25 | 2017-12-13 | 国立大学法人広島大学 | Dna結合ドメインを含むポリペプチド |
| JP7045643B2 (ja) | 2018-05-28 | 2022-04-01 | 日本電気硝子株式会社 | ガラス物品の製造方法及び製造装置 |
-
2020
- 2020-11-13 JP JP2021556173A patent/JPWO2021095847A1/ja active Pending
- 2020-11-13 WO PCT/JP2020/042429 patent/WO2021095847A1/ja not_active Ceased
- 2020-11-13 CN CN202080090344.XA patent/CN114901812A/zh active Pending
- 2020-11-13 EP EP20887397.6A patent/EP4060038A4/en not_active Withdrawn
- 2020-11-13 TW TW109139772A patent/TW202124718A/zh unknown
- 2020-11-13 US US17/776,519 patent/US20230250415A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105683375A (zh) * | 2013-11-06 | 2016-06-15 | 国立大学法人广岛大学 | 用于插入核酸的载体 |
| WO2018025206A1 (en) * | 2016-08-02 | 2018-02-08 | Kyoto University | Method for genome editing |
| WO2019073965A1 (ja) * | 2017-10-10 | 2019-04-18 | 国立大学法人広島大学 | エフェクターT細胞(Teff)抗原受容体を用いた抗原特異的制御性T細胞(Treg)の作出技術 |
| WO2019073964A1 (ja) * | 2017-10-10 | 2019-04-18 | 国立大学法人広島大学 | Platinum TALENを用いたT細胞受容体の完全置換技術 |
| WO2019084552A1 (en) * | 2017-10-27 | 2019-05-02 | The Regents Of The University Of California | TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS |
Non-Patent Citations (1)
| Title |
|---|
| 韩冰舟;张亚鸽;张博;: "基因组靶向敲入技术在模式动物中的发展与应用:以斑马鱼为例", 生命科学, no. 09 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021095847A1 (ja) | 2021-05-20 |
| EP4060038A4 (en) | 2024-07-10 |
| TW202124718A (zh) | 2021-07-01 |
| US20230250415A1 (en) | 2023-08-10 |
| JPWO2021095847A1 (cg-RX-API-DMAC7.html) | 2021-05-20 |
| EP4060038A1 (en) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113272435B (zh) | 在多个主要组织相容性复合体分子上受限的ny-eso-1特异性t细胞受体的组合物 | |
| CA2474161C (en) | Concatemers of differentially expressed multiple genes | |
| CN101768616B (zh) | 含稳定聚合酶的反应化合物的干组合物 | |
| CA2474172C (en) | A library of a collection of cells | |
| AU2019368215B2 (en) | Engineered enzymes | |
| AU2019236288B2 (en) | Methods and compositions for inducible expression of neurotrophic factors | |
| RU2763170C2 (ru) | Производство олигосахаридов человеческого молока в микроорганизмах-хозяевах с модифицированным импортом/экспортом | |
| CA2683497C (en) | .delta.8 desaturases and their use in making polyunsaturated fatty acids | |
| KR102942447B1 (ko) | 위스콧-알드리치(Wiskott-Aldrich) 증후군에 대한 조혈 줄기 세포-유전자 치료요법 | |
| KR102652494B1 (ko) | 전장 t-세포 수용체 오픈 리딩 프레임의 신속한 조립 및 다양화를 위한 2-성분 벡터 라이브러리 시스템 | |
| CN110402085A (zh) | 用于生物控制植物病原体的系统和方法 | |
| CN109689856A (zh) | 用于海藻宿主细胞的CRISPR-Cas系统 | |
| US20040110174A1 (en) | Concatemers of differentially expressed multiple genes | |
| CN104152572B (zh) | 同时检测三种链球菌的三重实时荧光pcr方法及试剂盒 | |
| CN113302303B (zh) | 经修饰的丝状真菌宿主细胞 | |
| CN101883843A (zh) | 破坏过氧化物酶体生物合成因子蛋白(pex)以改变含油真核生物中多不饱和脂肪酸和总脂质含量 | |
| CN114480153B (zh) | 一种生产维生素a的酿酒酵母菌及其构建方法 | |
| CN109517846A (zh) | 基于CRISPR/Cas9系统高通量构建棉花突变体库的方法 | |
| CN116670157A (zh) | 用于抗淋病奈瑟球菌的疫苗接种的组合物和方法 | |
| KR102898438B1 (ko) | 리소좀 축적병을 완화시키기 위한 렌티벡터-형질도입된 t-rapa 세포의 용도 | |
| US6537767B1 (en) | Method for screening antimycotically active substances | |
| CN111867637B (zh) | 新ehv插入位点ul43 | |
| KR20230134524A (ko) | 무장된 세네카 밸리 바이러스 종양용해 요법 조성물및 그의 방법 | |
| CN117147870B (zh) | 一种基于双细胞系统的抗骨硬化蛋白抗体活性检测方法 | |
| KR102160215B1 (ko) | 자일로스 이용능이 개선된 야로위아 리폴리티카 균주 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220812 |
|
| WD01 | Invention patent application deemed withdrawn after publication |